Clear the Noise: Improving Resolution of GLP-1 Receptor Agonist and Insulin Impurities
In the race to launch GLP‑1 generics and novel agonists, complex impurity analyses directly impact your speed to market. Conventional columns often obscure peaks of critical impurities, leading to costly rework and increased regulatory scrutiny.
Join us and learn about new analytical tools designed to streamline your process and deliver reproducible, high-resolution separations of GLP‑1 receptor agonists (GLP-1 RAs) and insulin-related impurities without relying on suppressive mobile‑phase additives.
Learn how improved resolution can accelerate method development, increase confidence in your results, and support faster time to market for your GLP-1 RA and insulin products.
In this webinar you will learn:
- How to gain greater resolution for your GLP-1 RA and insulin impurity analysis separations
- How to achieve up to 3x faster separations
- How to identify subtle impurities, such as single amino-acid substitutions and deamidation, beyond the detection limits of conventional reversed-phase technologies
Who should attend
This webinar is designed for you if you work in:
- Analytical development
- Process development
- R&D
- CXOs dealing with GLP-1 RAs or insulin
Presenter: Michael Zagieboylo (Principal Product Manager, Waters Corporation)
Michael Zagieboylo is a Principal Product Manager at Waters Corporation whose responsibilities involve assisting in the development and commercialization of innovative reagents and chromatography-based technologies for the separation, purification, and characterization of biological molecules, focusing on peptide and protein separations.
Presenter: Steve Shiner (Senior Manager, R&D for Biopharma Solutions, Waters Corporation)
